Sector Expert: Andrew McDonald

Gemphire Therapeutics , LifeSci Advisors

Image: Andrew McDonald

Andrew McDonald is cofounder of LifeSci Index Partners and coportfolio Manager of BioShares funds. He is an experienced healthcare investment professional with experience in identifying transformative products and technologies in all stages of development. Prior to cofounding LifeSci Advisors, McDonald served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, he was head of healthcare research and a biotechnology analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, he was a medicinal chemist at Cytokinetics, where he discovered and developed a promising anti-cancer agent. McDonald began his pharmaceutical career as a medicinal chemist at Pfizer. He received a Ph.D. in organic chemistry from UC Irvine and completed his bachelor's degree in chemistry at UC Berkeley.

Recent Interviews

Capture Growth with Baskets of Biotechs: LifeSci Advisors' Andrew McDonald (2/5/15)

Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which created the BioShares Biotechnology Clinical Trials and BioShares Biotechnology Products exchange-traded funds to limit risk. In this interview with The Life Sciences Report, McDonald describes how funds can be designed to grow on product sales and data generated via milestones in clinical development, and also names four companies he's included in the two portfolios.

Recent Quotes

— Andrew McDonald, LifeSci Advisors (11/27/13)
more >

"NBS has near-term catalysts and a deep pipeline."

— Andrew McDonald, LifeSci Advisors (11/12/13)
more >

"RXII's second phase I trial confirmed the mechanism of action and a strong safety profile for RXI-109."

— Andrew McDonald, LifeSci Advisors (7/15/13)
more >

"RXII announced the successful completion of its first phase 1 clinical trial for RXI-109."

— Andrew McDonald, LifeSci Advisors (6/11/13)
more >

"RXII has greatly strengthened its intellectual property position."

— Andrew McDonald, LifeSci Advisors (3/7/13)
more >

Due to permission requirements, not all quotes are shown.